Cardinal Health Inc. / Syncor International Corporation

Nuclear Medicine / Radiopharmaceutical Diagnostics & Therapy

Disease Overview

Nuclear pharmacy services prepare patient-specific radiolabeled drugs (primarily Tc-99m-based diagnostic tracers, plus PET FDG and therapy isotopes) and deliver them to hospitals on tight half-life-driven schedules. The service is volume-dependent, regulated, and has high barriers to entry given short isotope half-lives.

Competitive Landscape

In 2003, the US nuclear pharmacy services market was a duopoly: Syncor International held the largest dispensing network (~130 nuclear pharmacies), with Cardinal's own central pharmacy services unit second, and Mallinckrodt/Tyco and a long tail of regional operators behind. The combined Cardinal-Syncor entity became the unambiguous #1 in radiopharmaceutical compounding and unit-dose distribution, capturing scale advantages tied to Tc-99m supply chains from Mo-99 generator manufacturers. The Syncor fraud disclosure (questionable overseas payments uncovered late 2002, settled with DOJ/SEC) reduced deal value from ~$1.1B to ~$760M but did not derail closing on January 1, 2003, with Syncor shareholders receiving 0.47 Cardinal shares each. The deal preceded the PET imaging boom (FDG, then later therapeutics) and positioned Cardinal for the radiopharmaceutical resurgence — though Cardinal later divested portions of the nuclear pharmacy business to Patient Care Infusion (FTC-approved 2012). Competing distributors (PETNET, IBA Molecular) emerged as PET volume grew.